Wall Street Signals: Immune Pharmaceuticals Inc (IMNP) CEO Acquires $24,428.00 in Stock

Immune Pharmaceuticals Inc (IMNP) CEO Acquires $24,428.00 in Stock

$IMNP Immune Pharmaceuticals Inc (NASDAQ:IMNP) CEO Daniel Gedeon Teper acquired 39,400 shares of the firm’s stock in a transaction on Tuesday, January 12th. The shares were bought at an average cost of $0.62 per share, for a total transaction of $24,428.00. Following the completion of the acquisition, the chief executive officer now directly owns 4,724,705 shares of the company’s stock, valued at approximately $2,929,317.10. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Daniel Gedeon Teper also recently made the following trade(s):
  • On Tuesday, January 5th, Daniel Gedeon Teper bought 62,000 shares of Immune Pharmaceuticals stock. The stock was bought at an average cost of $0.81 per share, with a total value of $50,220.00.

Today’s Trading

Immune Pharmaceuticals Inc (NASDAQ:IMNP) opened at 0.54 on Friday. Immune Pharmaceuticals Inc has a one year low of $0.49 and a one year high of $2.28. The stock has a 50 day moving average price of $0.75 and a 200 day moving average price of $1.28. The firm’s market capitalization is $16.35 million.
Immune Pharmaceuticals (NASDAQ:IMNP) last issued its earnings results on Thursday, November 12th. The biopharmaceutical company reported ($0.35) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.18) by $0.17. On average, equities analysts predict that Immune Pharmaceuticals Inc will post ($0.63) EPS for the current fiscal year.

Analyst Ratings

IMNP has been the topic of several recent analyst reports. Roth Capital initiated coverage on Immune Pharmaceuticals in a research note on Thursday, October 8th. They issued a “buy” rating and a $6.00 price target on the stock. Chardan Capital lifted their price objective on Immune Pharmaceuticals from $5.00 to $6.50 and gave the company a “buy” rating in a report on Tuesday, October 13th. Finally, FBR & Co. restated an “outperform” rating on shares of Immune Pharmaceuticals in a research note on Friday, October 30th.

Immune Pharmaceuticals Company Profile

Immune Pharmaceuticals Inc. is a United States-based clinical stage biopharmaceutical company. The Company is engaged in the development and commercialization of targeted therapeutics, including monoclonal antibodies, nano-therapeutics and antibody drug conjugates, for the treatment of inflammatory diseases and cancer. Its pipeline includes, Bertilimumab, which is a clinical-stage human antibody, targeting eotaxin-1, which is involved in a number of immune mediated diseases; NanomAbs, which is a technology platform that allows the targeted delivery of chemotherapeutics into cancer cells, and AmiKet, which is a topical neuropathic pain drug candidate. The Company’s oncology pipeline includes Crolibulin, which is a small molecule vascular disrupting agent and apoptosis inducer for the intended treatment of patients with solid tumors, and Azixa, which is a vascular disruptive agent in development for the treatment of primary brain cancers and metastatic tumors with brain involvement.